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Abstract
Hypoglycemia is the most frequent metabolic abnormality in the newborn, but no con-
sensus exists on what level of blood glucose is able to protect the brain and influence the 
child’s neural development and which is the best course of management in cases labeled 
as hypoglycemia. Early diagnosis, urgent treatment, and prevention of future episodes of 
hypoglycemia are the cornerstones of management, now supported by recent advances 
in molecular genetics and in our understanding of the pathophysiology of neonatal hypo-
glycemia, particularly the pathogenesis of congenital hyperinsulinemic hypoglycemia.
Keywords: hypoglycemia, newborn, molecular mechanisms, hyperinsulinemia, actual 
treatment
1. Introduction
Hypoglycemia is the most frequent metabolic abnormality in the newborn, and although it 
is the most common biochemical disorder in this age group [30], it is still a source of clini-
cal concern and controversy, as no consensus exists on what level of blood glucose is able to 
protect the brain and influence the child’s neural development [6, 22, 53] and which is the 
best course of management in cases labeled as hypoglycemia. Early diagnosis, urgent treat-
ment, and prevention of future episodes of hypoglycemia are the cornerstones of manage-
ment, now supported by recent advances in molecular genetics [48] and in our understanding 
of the pathophysiology of neonatal hypoglycemia, particularly the pathogenesis of congenital 
hyperinsulinemic hypoglycemia [12].
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
Comm ns Attribution Lic nse (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
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Hypoglycemia occurs in 1.3–4.4 per 1000 full-term newborns and 15–55 per 1000 preterm 
newborns. This suggests that gestational age has enormous influence on its onset; in cer-
tain groups, adaptive mechanisms are not adequately developed, which predisposes them 
to increased risk of hypoglycemia. According to current evidence, the prevalence of hypo-
glycemia is approximately 10% in full-term neonates [45]; 6.5% in appropriate for gestational 
age (AGA), 8% in large for gestational age (LGA), and 15% in small for gestational age (SGA) 
newborns; and 15.5% in late-preterm infants [7].
2. Metabolic aspects
The maintenance of physiological concentrations of glucose in newborns plays important 
roles, including protecting the brain from damage caused by insufficient glucose intake and 
preventing the consequences of hyperosmolarity caused by high glucose concentrations. 
Although glucose is the preferred energy source of neurons, other sources, such as lactate and 
ketone bodies [23], seem to exert a neuroprotective effect. However, in hypoketotic states, such 
as hyperinsulinism or fatty acid oxidation disorders, ketone and lactate concentrations are not 
high enough to replace glucose, and the risk of a cerebral energy deficit is greater [60, 61].
It is known that, during fasting, several metabolic systems are activated to prevent hypogly-
cemia, which may be seen as a failure in one of these systems or as an abnormality affecting 
one or more of the hormones that control these systems [24].
As the brain mass of newborn infants in relation to body size is larger than that of adults, the 
rate of glucose utilization per kg body weight in newborns is two- to threefold than that of 
adults (4–6 mg/kg/min) [61].
2.1. Maternal provision of glucose to the fetus
The first half of pregnancy is characterized by marked anabolism. In early pregnancy, 
increased caloric intake not only supports fetal development but also facilitates fat deposition 
in the mother in preparation for the second half of pregnancy, a period of accelerated fetal 
growth in which maternal stores are mobilized to meet the needs of the fetus. To this end, 
increased insulin secretion also occurs in early pregnancy, as a way to store energy.
From the midpoint of pregnancy onward, high levels of circulating maternal insulin are also 
observed, but high levels of anti-insulin factors override this effect, ensuring the provision of 
nutrients to the fetus during the postprandial period. Thus, in pregnant women with preex-
isting diabetes, the effects of these anti-insulin factors are potentiated, causing excess provi-
sion of glucose and other energy sources to the fetus and thus triggering the abnormalities 
observed in infants born to diabetic mothers.
In the expectant mother, glucose is found at levels 25–30% higher than in the fetus, and it 
is transported to the fetus by concentration gradients and simple diffusion and through the 
action of transporters. In the fetus, the predominant transporter is GLUT-1, which has a high 
affinity for glucose and facilitates its passage through tissues [28].
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Most glucose in the fetus undergoes oxidation to supply its energy needs, while another 
part contributes significantly to a buildup of glycogen, protein, and fat in triglyceride form. 
Glucose is the most important source of energy for the fetus and the major substrate for brain 
metabolism.
2.2. Glucose uptake in the newborn
At birth, the fetus becomes dependent on itself to obtain energy and meet the metabolic needs 
of its vital organs, particularly the central nervous system (CNS). Each mole of oxidized glu-
cose provides 38 moles of adenosine triphosphate (ATP) [54].
Cerebral glucose transport takes place through a facilitated diffusion process, which is depen-
dent on glycemia and is not regulated by insulin. Protection against hypoglycemia is coordinated 
by the autonomic nervous system by means of hormones that stimulate the production of glu-
cose (through glycogenolysis and gluconeogenesis) and limit peripheral glucose utilization [54].
Glycogen is the only glucose storage medium in the body. Its deposits are found in the liver, 
striated muscle tissue (including cardiac muscle), kidneys, bowel, brain, and placenta.
The fetal liver contains a complete enzyme system for the synthesis and breakdown of glyco-
gen, levels of which are low in early pregnancy but rise slowly and steadily from gestational 
weeks 15–20, before peaking in the third trimester. At this time, fat deposition also increases. 
Thus, part of the energy and substrates used for fetal growth is redirected for storage, which 
will play an important role in the peripartum and postpartum periods.
Hepatic glycogenolysis is the major mechanism of glucose release in the immediate neonatal 
period, which leads to depletion of glycogen stores. It is induced by an increase in glucagon and 
catecholamines and a reduction in insulin. This exhaustion of glycogen stores promotes activa-
tion of gluconeogenesis, which occurs largely as a result of free fatty acid oxidation in the liver.
Glucose homeostasis will thus depend on glucose intake; gluconeogenesis; glycogen, protein, 
and fat stores; and hormonal and neural factors.
Glucose produced from the breakdown of dietary lactose into galactose and glucose, for 
instance, is not taken up by the liver in the neonatal period; the newborn is thus dependent on 
hepatic gluconeogenesis to sustain glucose production.
Once glycogen stores are low, gluconeogenesis induced by glucagon, catecholamines, cortisol, 
and growth hormone mobilizes fat and protein substrates. Insulin, thyroid hormone, cortisol, 
and glucagon systematically promote induction of specific enzymes, thus adapting the neo-
nate to the abrupt cessation of the supply glucose that was provided continuously before birth.
Upon clamping the umbilical cord, the maternal glucose supply, which was 54 mg/dL during 
pregnancy, ceases abruptly, and the neonate’s blood glucose levels decline rapidly and precipi-
tously—from a concentration similar to that of the mother to approximately 41 mg/dL within 
the first 6 h of life. Physiologically, glucose concentration decreases to approximately 30 mg/
dL in the first 2 h after birth, subsequently rises, and plateaus at approximately 45 mg/dL 12 h 
after birth.
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3. Definition
Current evidence is still unable to define a specific glucose concentration that is safe to pre-
vent acute neurological damage or chronic, irreversible neurological injury in the neonate. 
Weight and gestational age, as well as the age at onset, severity, duration, and number of epi-
sodes of hypoglycemia, are all determinants of the blood glucose level most appropriate for 
protection of the neonatal brain [54]; thus, doubts persist as to whether any single level may 
represent a red flag for neurological safety.
A plasma glucose level below 30 mg/dL (1.65 mmol/L) in the first 2 h of life or below 45 mg/dL 
(2.5 mmol/L) after these first 2 h has been considered diagnostic of hypoglycemia [54].
Various situations can influence the appropriateness of a blood glucose level for use as a cut-
off point for treatment initiation, including nutritional timing and the presence and absence 
of symptoms [64]. Thus, in 2011, the American Academy of Pediatrics proposed that neonatal 
hypoglycemia be defined as a blood glucose level of 2.5 mmol/L before routine feeding [1, 
20]. Other studies suggest a limit of 2 mmol/L in asymptomatic newborns and 2.5 mmol/L in 
symptomatic neonates [42]. Although cutoff values below 2.6 mmol/L have been cited in vari-
ous studies as defining of neonatal hypoglycemia, there is no guarantee that such a concentra-
tion is the most appropriate choice for establishing a diagnosis of this disorder and prompting 
initiation of treatment. An important finding reported by McKinlay et al. [34] has encouraged 
neonatologists to consider a glucose concentration >47 mg/dL as the level at which no impair-
ment of appropriate neurological development was observed at age 2 years.
These proposed levels serve to provide a margin of safety until additional data are available 
to support a more accurate definition. However, the potential risk of neurologic sequelae has 
led many authors to consider blood glucose values <50 mg/dL in infants as the limit beyond 
which treatment should be instituted [61].
In practice, blood glucose levels below 50 mg/dL as measured by a glucometer should war-
rant careful monitoring, and plasma glucose levels below 45 mg/dL should prompt initiation 
of diagnostic measures and immediate treatment.
4. Etiology and pathogenesis
Overall, neonatal hypoglycemia is caused by one of the three main mechanisms: situations 
associated with hyperinsulinemia, situations associated with low or depleted glycogen stores, 
and situations associated with excessive glucose consumption. These mechanisms may also 
be compounded by the effects of certain drugs used in pregnancy.
4.1. Situations associated with hyperinsulinemia
4.1.1. Infant born to a mother with diabetes
Offspring of diabetic mothers may be abnormally large at birth (LGA), even when the mother 
was able to keep blood glucose within normal or near-normal range throughout pregnancy. 
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The risk of birth defects is two to four times higher in fetuses of pregnant women with dia-
betes, particularly when the disorder is poorly controlled during the period of fetal organ 
development (i.e., gestational weeks 6–7), and the neonatal mortality rate is fivefold than that 
of infants born to women without diabetes.
Intermittent maternal hyperglycemia causes fetal hyperglycemia, which, in turn, stimulates 
excess insulin production by the fetal pancreas. On the one hand, this increased fetal insulin 
synthesis stimulates excess organ growth (except of the brain and liver, which are not depen-
dent on insulin supply for growth), thus causing fetal macrosomia. On the other hand, it is 
associated with a high incidence of neonatal hypoglycemia and marked lipolysis during the 
first few hours after birth. Hyperinsulinism and hyperglycemia may also cause fetal acidosis, 
which results in an increased rate of stillbirths. Although hyperinsulinemia is probably the 
leading cause of hypoglycemia, reduced epinephrine and glucagon responses can also be 
contributing factors. Levels of cortisol and growth hormone are normal [11].
Increased levels of glycated hemoglobin in fetal blood appear to precipitate tissue hypoxia, as 
this form of hemoglobin has high affinity for oxygen molecules.
Furthermore, chronic fetal hyperinsulinemia increases metabolic rates, thus increasing oxy-
gen consumption and inducing relative hypoxemia; this, in turn, boosts red blood cell produc-
tion, causing polycythemia and, consequently, hemolysis and neonatal hyperbilirubinemia. 
Severe hypoxemia can ultimately lead to fetal death.
After birth, the supply of glucose to the fetus is cut off, but hyperinsulinemia persists, speed-
ing both exogenous glucose utilization and endogenous glucose production; this phenomenon 
may last approximately 3 days, until normal insulin secretion is established. Hypoglycemia 
may manifest in the intervening period.
4.1.2. Large for gestational age status
LGA neonates may also develop hypoglycemia [44], through the same mechanism observed 
in infants born to diabetic mothers; however, in these infants, blood glucose reaches normal 
levels within the first few hours of life [32].
4.1.3. Congenital hyperinsulinemic hypoglycemia
Hypoglycemia associated with congenital hyperinsulinism (CHH), also known as persistent 
hyperinsulinemic hypoglycemia of infancy (PHHI), is the result of inappropriate insulin 
secretion or hyperinsulinism. In infants with this disease, hypoglycemia is triggered by fast-
ing and is always accompanied by an increase in plasma insulin concentrations, which are 
usually inappropriately high for the concomitant low blood glucose concentration. The dis-
ease appears to be more closely related to an increase in global endocrine functional activity 
of the pancreas rather than an increase in the number of pancreatic beta cells.
CHH is an important etiology that should be considered in cases of persistent and difficult-
to-control hypoglycemia. It is a medical emergency that requires precise etiological diagnosis 
and represents a serious therapeutic challenge. The term PHHI was first proposed by Glaser in 
1989 [19] and has since come to replace the now-outdated terms nesidioblastosis and islet-cell 
Neonatal Hypoglycemia
http://dx.doi.org/10.5772/intechopen.69676
67
dysmaturity syndrome to describe pancreatic abnormalities associated with hypoglycemia 
and hyperinsulinism.
Most cases of CHH are sporadic (1:40,000–50,000 live births), but a higher prevalence has been 
described in communities with a high degree of consanguinity. This familial form associated 
with inbreeding may occur in up to 1:2500 live births. Thus, an autosomal recessive inheri-
tance pattern has been posited to explain it. There is no evidence of sex predominance, and the 
maternal history is generally negative; however, a careful history may reveal prior neonatal 
deaths or unexplained seizures or mental retardation in other siblings.
Patients with CHH are mostly LGA, as a consequence of hyperinsulinism, but without signifi-
cant hepatomegaly. They exhibit persistent symptoms of hypoglycemia, including hypoto-
nia, cyanosis, apnea, and difficult-to-control seizures, as early as the neonatal period. Sudden 
infant death is also seen in patients with CHH. Although the condition is rare, the high fre-
quency of brain damage and developmental delay as a result of severe, treatment-refractory 
hypoglycemia in these patients justifies the need for early etiologic diagnosis and immediate 
treatment.
Currently, the most accepted etiogenic hypothesis for the dysfunction of CHH is inappropri-
ate insulin secretion by pancreatic beta cells. The molecular basis of congenital hyperinsulin-
ism involves defects in key genes that regulate the complex mechanism of insulin secretion 
control [12]. Nine genes have been identified and classified within the potassium channelopa-
thies (ABCC8, KCNJ11) and metabolic disorders (GLUD1, GCK, HNF4A, HNF1A, SLC16A1, 
UCP2, HADH) [47, 52]. Genetic defect mutations involving the ABCC8/KCNJ11 genes, which 
encode the SUR1/Kir 6.2 components of the ATP-sensitive potassium channels (K
ATP
) in pan-
creatic beta cells, are the most common [13, 27]. In normal cells, the K
ATP
 channels remain open 
or closed in response to variation in blood glucose levels, which leads to changes in the action 
potential of the cell membrane. An increase in blood glucose raises the rate of glucose metabo-
lism in beta cells, resulting in increased adenosine triphosphate (ATP) and decreased adenos-
ine diphosphate (ADP) within the cell, triggering closure of K
ATP
 channels and subsequent 
depolarization of the beta-cell membrane. This change in potential opens voltage-dependent 
calcium channels and leads to calcium influx. The subsequent increase in the cytosolic cal-
cium concentration stimulates exostosis of insulin secretory granules; thus, insulin is released 
continuously.
The potassium channel is a complex of two proteins: SUR1, a receptor with high affinity for 
sulfonylureas, and Kir 6.2, which forms the inner pore of the channel and maintains its align-
ment [39, 58, 59]. The regulatory genes of the sulfonylurea receptor and potassium channels 
were recently mapped to region 11p15.1 of chromosome 11. Individually; none of these pro-
teins has the ability to act as a potassium channel. Depending on the type of mutation affect-
ing the genes that regulate these proteins, CHH may manifest with three distinct phenotypes. 
The first represents the familial form, with truncation of SUR1 and the absence of K
ATP
. These 
patients have the most severe form of CHH and, in most cases, respond poorly or not at all 
to clinical treatment. In the second type, which accounts for sporadic cases, there is loss of 
K
ATP
 function but partial response to clinical treatment, due to formation of new potassium 
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ion channels. In the third type, onset is delayed and severity is mild, as these patients have 
functional K
ATPs
 and respond to clinical treatment.
A diagnosis of CHH is usually considered when hypoglycemia develops shortly after birth 
and requires glucose infusion at high rates, usually exceeding 10 mg/kg/min and occasionally 
up to 15–20 mg/kg/min. Typically, these infants have high blood levels of insulin, sometimes 
exceeding 10 μU/mL, and the insulin (μU/mL)-to-glucose (mg/dL) ratio is 1:4 or higher.
Beta-cell adenomas are characterized by marked, early onset hyperinsulinemia. These tumors 
require surgical removal or partial pancreatectomy. They are uncommon in the neonatal 
period. Definitive diagnosis can only be established through histopathology, and immuno-
histochemical study may be required.
4.1.3.1. Beckwith-Wiedemann syndrome
Beckwith-Wiedemann syndrome is one of the most common overgrowth disorders and can be 
identified in more than 75% of neonates above the 90th percentile for weight and length. It is 
estimated to occur in 1 in 13,700 births, but mild cases may lead to underestimation of its true 
frequency [31]. There is no gender predominance. The syndrome is characterized by gigantism, 
omphalocele, and macroglossia, a triad that occurs in over 80% of cases. Other abnormalities 
that occur less frequently include earlobe creases and posterior helical ear pits, microcephaly, 
wide fontanels, a prominent occipital protuberance, facial nevus flammeus, nonspecific cardiac 
defects, abdominal wall defects (umbilical hernia, diastasis recti), visceromegaly, and hyper-
plasia of the kidneys, pancreas, adrenal cortices, gonadal interstitial cells, and pituitary [50].
Neonatal hypoglycemia occurs in at least 50% of cases of Beckwith-Wiedemann syndrome. It 
is generally serious and may be associated with future mental retardation. Thus, early diag-
nosis is important for proper treatment of low serum glucose levels, to prevent neurological 
damage. It is believed that hypoglycemia in this syndrome is secondary to hyperinsulinism 
caused by beta-cell hyperplasia and hypertrophy, but glucagon deficiency and a reduction in 
somatostatin-producing delta cells have also been documented.
There is a clear evidence of genomic influence in the development of Beckwith-Wiedemann 
syndrome. A mutation in 11p15.5, a region that encompasses multiple gene loci, has been 
implicated [37].
4.1.3.2. Congenital hyperinsulinemic hypoglycemia and other syndromes
CHH has been described in other diseases and syndromes, including congenital hypothyroid-
ism [29], Sotos syndrome [4], Costello syndrome [21], Donohue syndrome [63], and Kabuki 
syndrome [62].
4.2. Situations associated with low or depleted glycogen stores
Prematurity and intrauterine growth restriction are among the situations that can influence 
neonatal blood glucose levels [35].
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4.2.1. Prematurity
As very low-birth-weight preterm infants have limited glycogen stores, gluconeogenesis is 
their main source of glucose production. Gluconeogenesis is induced by decreased glucose 
intake, as well as by high cortisol, catecholamine, and glucagon levels.
Increased neurologic morbidity is particularly common in children with severe, recurrent 
hypoglycemia. Experimental observations have stressed the resistance of the immature 
brain to damage caused by hypoglycemia. This resistance is a consequence of compensatory 
increase in blood flow to the brain, reduced energy needs, increased endogenous carbohy-
drate stores, and ability to take up and consume alternative organic substrates while saving 
glucose for energy production [36].
4.2.2. Intrauterine growth restriction
As a result of intrauterine growth restriction, SGA neonates may exhibit several abnormali-
ties shortly after birth, including increased susceptibility to infections, pulmonary hemor-
rhage, hyperbilirubinemia, and hypoglycemia. The widely varying incidence of the latter 
may reflect the different etiologies of intrauterine growth restriction (e.g., poor maternal 
nutrition, mothers with advanced age, uteroplacental insufficiency, derangements in mater-
nal metabolism, or fetal infection). Furthermore, polycythemia and fetal and neonatal hypox-
emia, which are often seen in SGA infants, can themselves contribute to development of 
hypoglycemia [49].
SGA infants are most at risk of hypoglycemia. Of those who do develop it, 65% are premature 
and 25% are post-term. Hypoglycemia can be asymptomatic or symptomatic and is generally 
observed in the first 24 h of life.
The factors contributing to low blood glucose levels include inadequate hepatic glycogen 
stores due to the high brain-to-body-mass ratio of SGA infants, the glucose-dependent nature 
of cerebral oxidative metabolism, and high overall metabolic rates. Furthermore, a reduction 
in rates of gluconeogenesis is probably responsible for 1% of episodes of prolonged hypoglyce-
mia in SGA infants, as these infants exhibit high concentrations of gluconeogenesis precursors 
(such as alanine); this suggests an inability to convert these exogenous precursors into glucose.
Hypoglycemia combined with asphyxia is more damaging to the immature brain than either 
condition alone.
4.3. Situations associated with increased glucose consumption
Various situations can increase glucose consumption in the neonate. These include severe 
birth asphyxia [9], severe respiratory distress, and sepsis.
Perinatal asphyxia may initially feature hyperglycemia secondary to cortisol and catechol-
amine release; this is followed by hypoglycemia secondary to depletion of hepatic glycogen 
stores, mobilized in response to this excess glucose consumption. The association of hypogly-
cemia with transient hyperinsulinism has been described [18].
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The association of severe respiratory distress, from various causes, and hypoglycemia caused 
by increased glucose consumption has often been described.
Neonatal sepsis is defined as a clinical syndrome characterized by systemic signs of infec-
tion and bacteremia (detected by positive blood cultures) during the first month of life. It is 
becoming increasingly important due to the reduction of neonatal mortality among the most 
premature newborns and to the prolonged care of these infants in neonatal units.
Decreased glycogen stores, impaired gluconeogenesis, and increased peripheral glucose utili-
zation appear to be the factors responsible for hypoglycemia associated with sepsis, although 
the usual response to sepsis observed in animal models has been an increase in the rates of 
glucose turnover and gluconeogenesis, as the result of a counter-regulatory hormonal response 
[33]. Blunting of this process is observed only during the final stage of illness and serves as a 
marker of fulminant sepsis [38].
4.4. Drugs used in pregnancy
Drugs such as beta-adrenergic agonists [57], corticosteroids, thiazide diuretics, oral antidia-
betics, propranolol, labetalol [3], valproic acid [10], antidepressants (SSRIs) [40], phenytoin, 
and terbutaline [55], among others, can cause hypoglycemia in infants.
B. Zhu et al. (2016) [67] reported an association between metformin use by diabetic patients 
during pregnancy and a reduction in incidence of neonatal hypoglycemia when compared 
to mothers who used insulin. Metformin has proven an effective alternative for use in this 
patient population, although it can cross the placenta.
5. Manifestations and clinical diagnosis
In most cases, infants—even those at risk—are asymptomatic. Nevertheless, an infant who is 
apathetic and refusing feeds and has a feeble cry should heighten suspicion of hypoglycemia. 
In high-risk infants, major findings include fine tremors, acrocyanosis, seizures, and apnea; if 
left untreated, coma and death may follow.
After birth, neonates born to mothers with diabetes develop complications related to their 
hyperinsulinemic state. In the first 3 days of life, these infants may exhibit episodes of irri-
tability, tremor, and hyperexcitability or may present with hypotonia, lethargy, and weak 
suckling—manifestations consistent with early development of hypoglycemia and late onset 
of hypocalcemia. However, one must bear in mind that these infants are sometimes asymp-
tomatic and the absence of symptoms should not delay testing for hypoglycemia.
The presence of tachypnea in the first days of life may be a transient manifestation of hypogly-
cemia, hypothermia, polycythemia, heart failure, cerebral edema secondary to traumatic deliv-
ery (particularly in macrosomic infants), or asphyxiation. The incidence of respiratory distress 
syndrome is high in these infants, since hyperinsulinemia may alter fetal lung maturation, 
inhibiting the development of enzymes required for the synthesis of pulmonary surfactant.
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6. Laboratory diagnosis
Glucometry is the method of choice for initial screening of glucose levels, due to its use and 
minimal blood sample required; however, levels should be confirmed through laboratory 
measurement in plasma, especially when the glucometer reading is very low, as this method 
is rather imprecise at the lower limit of detection. Several factors can affect the values obtained 
by glucometry, such as the expiration date of the test strip, ambient temperature and humid-
ity in the storage environment, the presence of sugars other than glucose, metabolic acidosis, 
high PO
2
, hyperbilirubinemia, high hematocrit, and edema, among others [25, 66]. Several 
devices have been tested with the aim of demonstrating that their results may be unreliable 
and influence the management indicated by a reading [14].
7. Diagnostic imaging
A particular vulnerability of the occipital lobe to hypoglycemia has been observed on MRI 
[16], with no plausible explanation. Other authors have raised the possibility that variant 
anatomy of the circle of Willis and occipital lobe infarct may be implicated in these cases [2].
8. Treatment
As mentioned previously, there are still no clearly set values to define hypoglycemia in the 
first 2 h of life. It is known that, in the healthy, full-term neonate, blood glucose levels are low-
est between 30 and 60 min of life and rise thereafter to normal baseline values of 60–90 mg/dL 
between 90 and 180 min of life. This threshold should be considered the physiological goal or 
therapeutic target at which blood glucose levels should be maintained.
Although one may consider a diagnosis of hypoglycemia when plasma glucose levels are 
below 45 mg/dL, this is not an absolute cutoff. Depending on the etiology of hypoglycemia 
and, consequently, on the availability of alternative pathways for gluconeogenesis, patients 
may be symptomatic in the 45–60 mg/dL range, as in cases of fatty acid oxidation defects.
SGA and late-preterm infants should be fed every 2–3 h and screened before each feeding 
in the first 24 h. After 24 h, screening needs only be continued in those whose glucose levels 
remain below 50 mg/dL.
8.1. Newborns asymptomatic in the first 2 h of life
The need for treatment in these children has been called into question, as hypoglycemia may 
be transient and may resolve spontaneously through stimulant counter-regulatory mecha-
nisms. In general, if the infant is asymptomatic, to start early breastfeeding without the need 
to draw blood for glucose measurement, formula feeding, or other special care.
However, in some newborns, this physiological process may fail, which may facilitate the 
development of hypoglycemia; therefore, the American Academy of Pediatrics suggests that 
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in the first hour of life, asymptomatic at-risk infants should have a glucose check 30 min after 
feeding; if the blood glucose level remains below 25 mg/dL and the infant is asymptomatic, it 
should be fed again and blood glucose reassessed 1 h after the first check [67].
8.2. Asymptomatic high-risk newborns
Late-preterm, LGA, SGA, and intrauterine growth restriction (IUGR) infants, as well as those 
born to diabetic mothers, are at particular risk of hypoglycemia. However, they are often 
asymptomatic. Breastfeeding followed by repeated glucose measurement has been the stan-
dard of care. However, if hypoglycemia persists despite frequent feedings, continuous intrave-
nous infusion of glucose may be indicated.
A dextrose infusion rate of 3–5 mg/kg/min may be used in infants born to diabetic mothers, 
both to prevent overstimulation of glucose secretion and because of the greater fat mass of these 
infants. A dextrose infusion rate of 4–7 mg/kg/min may be used in most full-term and late-pre-
term neonates. In IUGR neonates, a glucose infusion rate of 6–8 mg/kg/min is often necessary. 
A study in an animal model of IUGR revealed increased peripheral insulin sensitivity, which 
may be associated with increased glucose infusion requirements. However, some children with 
IUGR should be followed closely, especially preterm infants, who may develop hyperglycemia 
due to reduced insulin secretion and less muscle mass for glucose utilization. Continuous intra-
venous glucose infusion, usually preceded by an IV bolus of dextrose (200 mg/kg over 5 min), 
is also indicated if these newborns develop symptomatic hypoglycemia. However, the need for 
such massive glucose administration is hotly contested due to the risk of undesirable effects, 
particularly in very-low-birth-weight preterm infants. Complete or partial resolution of symp-
toms once glucose concentration is corrected is considered definitive proof that symptoms were 
caused by hypoglycemia. Nevertheless, IV dextrose infusions are not an entirely appropriate 
treatment; they cause discomfort to the infant, which is made worse by the need for placement 
of a deep IV catheter, the need for NICU admission, and physical separation of the newborn 
from the mother, which hinders timely initiation of breastfeeding. However, when adminis-
tered safely so as to prevent these complications, IV infusion of dextrose at low concentrations 
can be beneficial even in asymptomatic high-risk neonates.
8.2.1. Dextrose gel
Oral administration of glucose in gel form has been considered appropriate and should be 
part of any protocol to prevent episodes of hypoglycemia in asymptomatic newborns [41]. 
Current studies have shown that oral administration of 40% dextrose gel may reduce the 
occurrence of neonatal hypoglycemia by up to 70% [5] and should thus be considered as the 
first-line treatment in these patients [65].
8.3. Symptomatic newborns
8.3.1. Glucose
Symptomatic neonates should be treated with glucose intravenously, not orally. A 200 mg/kg 
bolus of glucose should be administered over 1 min (10% dextrose at 2 mL/kg). This should be 
followed by IV infusion at 6–8 mg/kg/min. Glucose levels should be monitored after 30–60 min, 
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with a therapeutic target of >45 mg/dL. Control measurements should be obtained every 1–2 h. 
Once levels are stable, they can be reassessed every 4–6 h. If values do not reach a normal range, 
the rate of glucose infusion is increased by 1–2 mg/kg/min every 3–4 h. In cases of hyperinsu-
linism, a rate of 15–30 mg/kg/min may be necessary. Oral feedings should only resume once 
blood glucose levels have been stable for 6 h.
High glucose concentrations (20–25%) may be necessary to maintain a rate of infusion of 
15–30 mg/kg/min; concentrations above 12.5% will require a central venous catheter [56].
8.3.2. Glucocorticoids
Physiologically, glucocorticoids promote increased resistance to insulin action, reduce the 
secretion of insulin, and activate enzymes involved in gluconeogenesis, mobilizing amino 
acids for this purpose. Thus, although such effects should theoretically induce an increase 
in blood glucose, there is no evidence to support glucocorticoid therapy in the treatment of 
hypoglycemia other than that caused by primary or secondary adrenal insufficiency.
Except in cases of hypoglycemia of self-limiting etiology (e.g., infants born to diabetic mothers), 
blood and urine samples should be drawn at the time of hypoglycemia for investigation of pos-
sible changes in energy and hormone metabolism (lactate, free fatty acids, ketones, insulin, cor-
tisol, growth hormone, urinary organic acids) before any specific medications are administered.
8.3.3. Glucagon
Endogenous glucagon is the counter-regulatory hormone of insulin, secreted by pancreatic 
beta cells. Physiologically, hypoglycemia induces glucagon secretion to raise glucose levels 
[43]. The administration of glucagon has proven to be quite effective in full-term and preterm 
neonates without hyperinsulinism. Serum sodium levels should be monitored during glu-
cagon infusion. Hyponatremia, thrombocytopenia, and a rare paraneoplastic phenomenon, 
called necrolytic migratory erythema, have been associated with continuous infusion of glu-
cagon. Hypertonic saline solution (3% sodium chloride) may be indicated to treat glucagon-
associated hyponatremia.
A dose of 0.02 mg/kg/dose has been recommended [43]. A 24-h continuous infusion has been 
used at doses of 20–40 μg/kg/h up to a maximum of 1 mg/day. A 50% rise in blood glucose 
is expected in normal infants. The effect is transient. Long-acting preparations are employed 
in patients with glucagon deficiency and, in combination with somatostatin, in the treatment 
of congenital hyperinsulinism. When the expected rise in blood glucose does not occur, the 
diagnosis of hepatic glycogen storage disease should be suspected.
8.3.4. Diazoxide
This agent is indicated in cases of hypoglycemia associated with hyperinsulinism.
Diazoxide is a benzothiazine derivative that acts by opening ATP-sensitive potassium chan-
nels, causing inhibition of insulin secretion by pancreatic beta cells. Therefore, patients with 
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genetic defects that affect SUR1 and Kir 6.2, the constituent proteins that form the ATP-
sensitive potassium channel, may not benefit from administration of this drug. The recom-
mended dose ranges from 10 to 15 mg/kg/day, divided in two or three oral doses, up to a 
maximum dose of 30 mg/kg/day. It promotes an increase in hepatic glucose production and 
decreases peripheral glucose utilization. Most of the drug is eliminated by glomerular filtra-
tion, and 90% of diazoxide is bound to albumin. Sodium and water retention, plasma volume 
expansion, edema, thrombocytopenia, anorexia, vomiting, ketoacidosis, and hyperuricemia 
are possible complications of the use of this drug [17].
When the drug is effective, blood glucose levels will return to normal range within 2–4 days. 
Any trial of diazoxide therapy should last at least 1 week before the possibility of treatment 
failure is considered. Onset of action occurs within 1 h of administration, and the duration of 
action is approximately 8 h, as long as renal function is normal.
Failure of diazoxide therapy suggests an abnormality in ATP-sensitive potassium channels. 
In these cases, a course of octreotide therapy, which acts further downstream on the insulin 
secretion pathway, is advised.
8.3.5. Octreotide
Octreotide was the first somatostatin analogue approved for clinical use, due to its more pro-
longed effect. This substance inhibits the secretion of glucagon, insulin, growth hormone, 
and thyrotropin, as well as the exocrine secretions of the bowel. Due to its ability to inhibit 
hormones, this drug can be used in infants with congenital hyperinsulinemic hypoglycemia 
[19]. A dose of 5–35 mcg/kg/day via subcutaneous injection has been recommended.
8.3.6. Sirolimus (rapamycin)
The management of diffuse hyperinsulinemic hypoglycemia, which does not respond to 
diazoxide, is a major therapeutic challenge. The successful use of sirolimus, both alone and as 
adjunctive therapy with octreotide, appears to be a potential alternative to subtotal pancre-
atectomy. Sirolimus is an immunosuppressant that inhibits the activation and proliferation 
of T lymphocytes, with effects downstream of the IL-2 receptor and other T-cell growth factor 
receptors.
In a study involving four patients with diffuse hyperinsulinemic hypoglycemia [46], therapy 
with sirolimus allowed discontinuation of intravenous infusions of dextrose and glucagon in 
all for patients and maintenance treatment with octreotide alone. At the end of the first year 
of life, the four patients continued to receive sirolimus and were normoglycemic, without any 
apparent major adverse events. Sevim Ünal et al. [63] reported the use of sirolimus in a neonate 
with CHH due to a KCNJ11 gene mutation who had already failed treatment with continu-
ous infusions of glucose (14 mg/kg/min) and prednisone (2 mg/kg/day). Addition of intensive 
therapy with multiple medications (diazoxide, chlorothiazide, octreotide, glucagon, and nife-
dipine) also failed to produce an adequate response. However, before partial pancreatectomy 
was attempted, at age 30 days, sirolimus therapy was instituted at a dose of 0.5 mg/m2/day. 
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Improvements in glycemic control were achieved, enabling progressive dosage reduction of 
the other drugs. At the time of publication, at age 5 months, the infant was on minimal doses 
of hyperglycemic agents and continued to receive twice-daily sirolimus at a dose of 0.3 mg/m2/
day, without any complications.
8.3.7. Exendin
Recently, exendin-(9-39), a GLP-1 receptor antagonist that raises blood glucose levels in 
adults, has been introduced as a possible novel therapy for management of hypoglycemia in 
patients with CHH. However, further studies on its effectiveness and safety are needed [8].
8.3.8. Other drugs
Growth hormone is used in cases of hypoglycemia associated with deficiency of this hormone 
or with hypopituitarism.
In cases of hypoglycemia due to persistent hyperinsulinemic hypoglycemia that does not 
respond to treatment with diazoxide, glucose, and sirolimus, partial pancreatectomy may be 
indicated.
9. Consequences
Recurrent or sustained hypoglycemia can cause neurological damage, mental retardation, 
epilepsy, and personality disorders [54]. Transient episodes of hypoglycemia are also associ-
ated with deficits in math learning around age 10 years [26].
Severe hypoglycemia can lead to impairment of cardiovascular function and is associated 
with high rates of neonatal mortality in very low-birth-weight infants [15].
Permanent brain damage is found in 25–50% of patients with recurrent severe symptomatic 
hypoglycemia under age 6 months. Furthermore, hypoxemia and ischemia may potentiate 
the permanent damage caused by hypoglycemia. The pathological changes described include 
gyral atrophy, reduced white-matter myelination, and cerebral cortical atrophy. It bears not-
ing that the cerebral infarctions characteristic of hypoxic-ischemic processes are absent in 
hypoglycemia-associated brain injury [51].
10. Final considerations
Newborns with risk factors for neonatal hypoglycemia or those which, although not con-
sidered at risk, exhibit poor suckling or inadequate breast milk intake should receive fol-
low-up monitoring and care after hospital discharge, so as to prevent possible undetected 
hypoglycemia.
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